Skip to main content
Premium Trial:

Request an Annual Quote

Opko Health Raises $31M in Private Stock Placements

Premium

Opko Health announced this week that it has raised $31 million through private stock placements with seven investment groups.

The money comes at a key time for Opko, which earlier this year said that a $20 million stock purchase by a group controlled by the company's chairman and CEO would only give it enough resources to continue operations into early 2010 (see RNAi News, 3/19/2009).

Under the terms of the most recent investment deals, Opko will issue 31 million shares of its common stock at $1 per share. During morning trading on the Nasdaq today, shares of the company were selling for $1.20 apiece.

Investors participating in the transactions include Vector Group, Chung Chia Company, Grandtime Associates, Gold Sino Assets, Oracle Partners, Oracle Institutional Partners, and Nora Real Estate.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more